Company: MYSZ
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000990
Chunk: 1320

Company: My Size, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 1320
---
 are currently outstanding as
of March 10, 2025 and our board of directors is authorized to issue additional shares of our common stock. Although our board of directors
intends to utilize its reasonable business judgment to fulfil its fiduciary obligations to our then existing stockholders in connection
with any future issuance of our capital stock, the future issuance of additional shares of our capital stock could cause immediate, and
potentially substantial, dilution to our existing stockholders, which could also have a material effect on the market value of the shares.
Further, other than certain participation rights that we have granted in a past offering, our shares do not have preemptive rights, which
means we can sell shares of our capital stock to other persons without offering purchasers in this offering the right to purchase their
proportionate share of such offered shares. Therefore, any additional sales of stock by us could dilute your ownership interest in our
Company.

Our
quarterly operating results may fluctuate significantly.

We
expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous
factors, including:

    ●
    variations
    in the level of expenses related to our research and development;

    ●
    any
    lawsuits in which we may become involved;

    ●
    regulatory
    developments affecting our products; and

    ●
    our
    execution of any collaborative, licensing or sales agreements, and the timing of payments under these arrangements.

33

If
our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could
decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock
to fluctuate substantially.

If
we fail to comply with the rules under the Sarbanes Oxley Act of 2002 related to accounting controls and procedures or if we discover
material weaknesses and deficiencies in our internal control and accounting procedures, our stock price could decline significantly and
raising capital could be more difficult.

If
we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness
of our internal control over financial